

- **Full Name:** Ji Soo Park, M.D., Ph.D.
- **Current Position & Affiliation:** Director & Clinical Associate Professor & Director,
Cancer Prevention Center, Yonsei Cancer Center
- **Country:** Republic of Korea

• **Educational Background:**

Feb.2006	Bachelor's degree & Doctor of Medicine (M.D.) Yonsei University College of Medicine, Seoul, Republic of Korea
Feb.2013	Master's degree, Department of Medicine, Graduation school of Yonsei University, Seoul, Republic of Korea
Feb.2018	Doctor's degree (Ph.D.) Department of Medicine, Graduation school of Yonsei University, Seoul, Republic of Korea

• **Professional Experience:**

Apr.2015 – Feb.2022	Clinical Assistant Professor Cancer Prevention Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Apr.2015 – Feb.2022	Deputy Director, Cancer Prevention Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Mar.2018 – present	Adjunct faculty, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
Mar.2022 – present	Clinical Associate Professor Cancer Prevention Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Mar.2022 – present	Director, Cancer Prevention Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea

• **Professional Organizations:**

- 2011- Korean Cancer Association
- 2011- Korean Society of Medical Oncology (former. Korean Association for Clinical Oncology)
- 2011- Korean Cancer Study Group – Subgroup of Palliative Care
- 2015- Korean Breast Cancer Society – the 8-10th Korean Clinical Practice Guideline for Breast Cancer Committee

- 2017- Korean Society of Cancer Prevention – an Assistant Manager (2019)
- 2021- Korean Academy of Supportive Care in Cancer – Public Relations Committee

• **Main Scientific Publications:**

1. Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, Kim TI, Lee ST. Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. *Cancer Res Treat*. 2017 Jan 17. doi: 10.4143/crt.2016.433.
2. Park JS, Lee ST, Nam EJ, Han JW, Lee JY, Kim J, Kim TI, Park HS. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. *BMC Cancer*. 2018 Jan 16;18(1):83. doi: 10.1186/s12885-017-3940-y.
3. Park JS, Lee ST, Han JW, Kim TI, Nam EJ, Park HS. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers. *Clin Breast Cancer*. 2018 Oct;18(5):362-373. doi: 10.1016/j.clbc.2018.02.007.
4. Park JS, Park JW, Shin S, Lee ST, Shin SJ, Min BS, Park SJ, Park JJ, Cheon JH, Kim WH, Kim TI. Application of Multigene Panel Testing in Patients With High Risk for Hereditary Colorectal Cancer: A Descriptive Report Focused on Genotype-Phenotype Correlation. *Dis Colon Rectum*. 2022 Jun 1;65(6):793-803. doi: 10.1097/DCR.0000000000002039. Epub 2022 May 3. PMID: 34897210.
5. Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer. *Cancer Res Treat*. 2021 Nov 17. doi: 10.4143/crt.2021.978. Epub ahead of print. PMID: 34793666.